WO2013044078A2 - Composites de polymères à teneur élevée en minéraux, élastomères et dégradables - Google Patents
Composites de polymères à teneur élevée en minéraux, élastomères et dégradables Download PDFInfo
- Publication number
- WO2013044078A2 WO2013044078A2 PCT/US2012/056641 US2012056641W WO2013044078A2 WO 2013044078 A2 WO2013044078 A2 WO 2013044078A2 US 2012056641 W US2012056641 W US 2012056641W WO 2013044078 A2 WO2013044078 A2 WO 2013044078A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- hydroxyapatite
- pela
- polymer
- block
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 66
- 229920000642 polymer Polymers 0.000 title description 23
- 229910052500 inorganic mineral Inorganic materials 0.000 title description 7
- 239000011707 mineral Substances 0.000 title description 7
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 149
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 144
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 229920001400 block copolymer Polymers 0.000 claims abstract description 33
- 239000000725 suspension Substances 0.000 claims abstract description 24
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 18
- 229920001577 copolymer Polymers 0.000 claims abstract description 8
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 55
- -1 poly(ethylene glycol) Polymers 0.000 claims description 36
- 239000007943 implant Substances 0.000 claims description 25
- 229920001223 polyethylene glycol Polymers 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 17
- 210000000988 bone and bone Anatomy 0.000 claims description 15
- 239000005977 Ethylene Substances 0.000 claims description 12
- 239000004310 lactic acid Substances 0.000 claims description 12
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 11
- 230000008093 supporting effect Effects 0.000 claims description 10
- 230000007547 defect Effects 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 239000011165 3D composite Substances 0.000 claims description 6
- 239000003124 biologic agent Substances 0.000 claims description 6
- 210000000845 cartilage Anatomy 0.000 claims description 6
- 210000003041 ligament Anatomy 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 230000005660 hydrophilic surface Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 210000002435 tendon Anatomy 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 230000017423 tissue regeneration Effects 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 1
- 201000009859 Osteochondrosis Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000000717 retained effect Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000000835 fiber Substances 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 238000001523 electrospinning Methods 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 238000010348 incorporation Methods 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 238000002411 thermogravimetry Methods 0.000 description 8
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 7
- 230000036571 hydration Effects 0.000 description 7
- 238000006703 hydration reaction Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000004626 scanning electron microscopy Methods 0.000 description 6
- 239000012620 biological material Substances 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000011067 equilibration Methods 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 5
- 238000001878 scanning electron micrograph Methods 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 238000007639 printing Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000002407 tissue scaffold Substances 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 238000011892 Von Kossa's method Methods 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000002293 adipogenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000000278 osteoconductive effect Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BOZRCGLDOHDZBP-UHFFFAOYSA-N 2-ethylhexanoic acid;tin Chemical compound [Sn].CCCCC(CC)C(O)=O BOZRCGLDOHDZBP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 241000906034 Orthops Species 0.000 description 2
- 102000004067 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000003462 bioceramic Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000002648 chondrogenic effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229920006237 degradable polymer Polymers 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101150023417 PPARG gene Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 229920000432 Polylactide-block-poly(ethylene glycol)-block-polylactide Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101150106167 SOX9 gene Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000000724 energy-dispersive X-ray spectrum Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- PTCGDEVVHUXTMP-UHFFFAOYSA-N flutolanil Chemical compound CC(C)OC1=CC=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 PTCGDEVVHUXTMP-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 238000010094 polymer processing Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000010069 protein adhesion Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 230000010512 thermal transition Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/32—Phosphorus-containing compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
- D01F6/78—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from copolycondensation products
- D01F6/84—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from copolycondensation products from copolyesters
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
- D01F6/78—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from copolycondensation products
- D01F6/86—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from copolycondensation products from polyetheresters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/16—Materials with shape-memory or superelastic properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/32—Phosphorus-containing compounds
- C08K2003/321—Phosphates
- C08K2003/325—Calcium, strontium or barium phosphate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K2201/00—Specific properties of additives
- C08K2201/018—Additives for biodegradable polymeric composition
Definitions
- the invention generally relates to polymer compositions. More particularly, the invention relates to compositions of hydroxyapatite and block co-polymers, methods of their preparation and uses thereof, wherein the co-polymers have hydrophilic and biodegradable hydrophobic blocks for stable interfacing with HA, resulting in stable polymer- hydroxyapatite suspensions suitable for a variety of applications.
- HA hydroxyapatite
- HA provides the necessary mechanical strength, enhances the material's osteoconductivity, and serves an important source for calcium and phosphate ions.
- HA also plays an important role in retaining a variety of proteins on its surfaces as it has been shown to support bone cell attachment and growth factor binding and release, and to expedite healing of bone defects in vivo.
- HA has been incorporated with synthetic polymers to form 2- or 3 -dimensional, dense or porous composite scaffolds using a wide range of fabrication techniques including electrospinning, injection molding, and 3 -dimensional prototyping.
- a widely used fabrication technology for generating porous thin membrane scaffolds (or fibrous meshes) is electrospinning, where a grounded surface collects a charged polymer jet of nano and/or micro-sized fibers.
- electrospinning where a grounded surface collects a charged polymer jet of nano and/or micro-sized fibers.
- Previously reported co-electrospinning of various polymers with hydroxyapatite suffers from a variety of limitations, such as material defects, settling of the hydroxyapatite, poor integration and brittleness, low strength and inferior surgical handling properties.
- beneficial effects occur when blending HA with hydrophilic polymers such as poly(hydroxyethyl methacrylate), for example improved toughness, elastic modulus and osteoblast adhesion, unfortunately poly(hydroxyethyl methacrylate) is not biodegradable.
- Biodegradable polyesters such as poly(lactic acid) (PLA) are readily electrospinable with established in vitro and in vivo degradation profiles.
- the intrinsic hydrophobicity of PLA results in its poor mixing and adhesion with hydrophilic HA, making it difficult to achieve adequate structural and mechanical properties in electrospun HA-PLA composite meshes.
- HA-PLA composites often exhibit inferior handling properties (e.g., brittleness) and inconsistent biological performance.
- Approaches for addressing the lack of interfacial adhesion include the addition of amphiphilic surfactants or modifying HA with surface-grafted polymers to improve interactions with hydrophobic polyesters.
- HA mixing and adhesion can be achieved through favorable hydrophilic interactions.
- hydrophilic polymers such as poly(hydroxyethyl methacrylate) (pHEMA) and poly(ethylene glycol) (PEG) have been reported. (Gaharwar, et al. 2011 Biomacromolecules 12, 1641-50; Song 2003 J.
- the invention provides novel compositions of hydroxyapatite and block copolymers, methods of their preparation and uses thereof, wherein the co-polymers have hydrophilic and biodegradable hydrophobic blocks for stable interfacing with HA, resulting in stable polymer-HA suspensions.
- the super-hydrophilicity, strengthened mechanical integrity, and retained structural integrity of the HA-poly(ethylene glycol-co-lactic acid) (PELA) composite in aqueous environment represent major advantages over the HA- poly(lactic acid) (PLA) composites for various skeletal tissue engineering applications.
- the invention generally relates to a composition that includes hydroxyapatite and a block co-polymer.
- the block co-polymer includes hydrophilic blocks and degradable hydrophobic blocks.
- the composition exhibits hydrophilic surface properties, elasticity and retains mechanical integrity in aqueous environment.
- the composition possesses a stable structural interface between the co-polymer and the hydroxyapatite.
- the composition of the invention is characterized by the properties of biodegradability, aqueous stability and eletrospinability.
- the composition may be electrospun into fibrous composite mesh.
- the block co-polymer is crosslinked to form a three-dimensional polymer-hydroxyapatite network.
- the block co- polymer/HA composite is extruded into an un-crosslinked three-dimensional scaffold by rapid prototyping (or 3-D printing).
- the invention generally relates to a medical implant that includes a composition comprising hydroxyapatite and a block co-polymer, wherein the block copolymer comprises hydrophilic blocks and degradable hydrophobic blocks.
- the implant may be a 3 -dimensional filler for bony defects or a repair material for bone, cartilage, osteochondral, tendon or ligament damage.
- the invention generally relates to a biodegradable composite scaffold prepared from a fibrous composite mesh electrospun from a suspension of hydroxyapatite with an amphiphilic block poly(ethylene gly col-co-lactic acid).
- the invention generally relates to a biodegradable, three- dimensional composite scaffold prepared by crosslinking a suspension of hydroxyapatite with an amphiphilic block poly(ethylene glycol-co-lactic acid).
- the invention generally relates to a biodegradable, three- dimensional composite scaffold, prepared by rapid prototyping from a suspension of hydroxyapatite with an amphiphilic block poly(ethylene glycol-co-lactic acid).
- FIG. 1 shows representative GPC spectrum and peak analysis for as-synthesized PELA.
- FIG. 2 shows exemplary 1H NMR spectrum for purified PELA.
- FIG. 3 shows exemplary photographs of stable PELA-HA (20% w/w HA) suspension over 1 week.
- FIG. 4 shows an exemplary electrospinning setup.
- FIG. 5 shows exemplary Von Kossa stain of PELA (A) PELA-HA (20% w/w HA) and (B) meshes. 100X magnification. 1 mL of Von Kossa stain (3% silver nitrate) was added to each mesh (1 cm 2 ) and placed in a UV crosslinker for 10 min. Samples were then washed 3 times with MilliQ water and imaged under a bright-field light microscope. [0021] FIG. 6 shows exemplary X-ray powder diffraction of PELA-HA mesh (33% w/w/
- FIG. 7 shows exemplary SEM of PELA (A), PELA-HA (33% w/w HA) (B), and
- FIG. 8 shows exemplary EDX spectra of PELA-HA (33% w/w HA) meshes.
- FIG. 9 shows (A) qualitative depiction of recoverable strain for PELA-HA (33% w/w HA) mesh, before (1), during (2), and after (3) manual elongation. (B) Tensile testing of electrospun composite meshes.
- FIG. 10 shows exemplary strain sweep data for PELA (A), PELA-HA (33% w/w HA) (B), and PELA-HA (50% w/w HA) (C) meshes.
- Mechanical testing was performed on a TA Instruments DMA Q800 dynamic mechanical analyzer under dry conditions at room temperature. Samples were cut into 5 mm X 15 mm strips and ramped at 1 Hz from 10 ⁇ to 200 ⁇ strain amplitude.
- FIG. 11 shows exemplary reaction scheme for the synthesis of PELA (1) and PLA (2).
- FIG. 12 shows exemplary microstructural, surface and compositional properties of electrospun PELA-HA and PLA-HA composite scaffolds.
- C TGA plots of electrospun scaffolds with HA powder as a control.
- FIG. 13 shows exemplary surface, mechanical and microstructural property changes of electrospun PELA-HA and PLA-HA composite scaffolds upon hydration.
- C SEM micrographs of scaffolds after 1-week incubation in PBS (pH 7.4, Ca 2+ /Mg 2+ -free) at 37 °C. Scale bar: 50 mm.
- FIG. 15 shows exemplary effect of scaffold composition (chemistry and HA content) on lineage commitment of rMSC under un-stimulated culture condition as
- FIG. 16 shows exemplary stability of HA (33% w/w) suspension in 1 :4
- FIG. 17 shows exemplary degradation of HA-PELA and HA-PLA scaffolds in PBS at 37 °C as monitored by mass reduction over 12 weeks.
- FIG. 18 shows exemplary macroporous 3-D PELA and HA-PELA composites prepared by 3-D prototyping.
- B Computer-assisted design (CAD) of the macroporous scaffold.
- FIG. 19 shows exemplary scanning electron microscopy (SEM) images of 3D- printed 10% HA-PELA scaffold. Top view (left) and cross section (right).
- This invention provides a novel biodegradable composite material: a stable suspension of HA with a block copolymer of poly(ethylene glycol) and poly(lactic acid).
- a block copolymer of poly(ethylene glycol) and poly(lactic acid) for example, disclosed herein is an electrospun, biodegradable amphiphilic block
- the block co-polymer fulfills key requirements, including HA integration, ease of processing (such as electrospinnability), aqueous stability, and biodegradability.
- the length of the PLA and PEG segments can be varied to modify the properties (mechanical, hydrophobicity, degradability) of the final polymer.
- PLA-PEG-PLA or PEG-PLA-PEG block copolymers can be synthesized depending on the application.
- This novel approach combines the degradability and aqueous stability of the poly(D,L-lactic acid) (PLA) block with the HA-binding capability of the poly(ethylene glycol) (PEG) block and the electrospinability of both.
- Electrospun PELA-HA composites exhibit a more uniform fiber morphology than those of electrospun PLA-HA composites.
- the HA- PELA composites are super-hydrophilic and compliant, enabling easy cell seeding and potential surgical manipulations. Equally important, the HA-PELA composite scaffolds more readily promote early osteochondral lineage commitment while suppressing the adipogenesis of bone marrow stromal cells in a HA-dose dependent manner than the HA-PLA composites.
- a key aspect of this invention is the use of a block co-polymer comprised of hydrophilic and degradable hydrophobic blocks for stable interfacing with HA, resulting in stable polymer-HA suspensions.
- the hydrophilic blocks are important for HA binding while the hydrophobic blocks allow for degradability and aqueous stability as well as
- This formulation can be crosslinked into a degradable three-dimensional (3- D) scaffold for filling bony defects or repairing bone, cartilage, osteochondral, tendon or ligament (such as anterior cruciate ligament) damage. It can also be extruded into fibers to serve as a degradable suture or as a material for fused deposition modeling machines, allowing for the printing of custom scaffolds.
- 3- D three-dimensional
- the example below describes one format (an electrospun 2-D fibrous composite mesh) for potential application as synthetic periosteum to expedite the healing (tissue integration) of structural bone allografts or 3-D tissue engineered bone constructs. This would function through the delivery of exogenous therapeutic agents (e.g., growth factors), enriching endogenous factors, and/or enabling the attachment and differentiation of stem or progenitor cells (endogenous or exogenous) at the implant site.
- exogenous therapeutic agents e.g., growth factors
- enriching endogenous factors e.g., growth
- the invention generally relates to a composition that includes hydroxyapatite and a block co-polymer.
- the block co-polymer includes hydrophilic blocks and degradable hydrophobic blocks.
- the composition exhibits hydrophilic surface properties, elasticity and retains mechanical integrity in aqueous environment.
- the composition possesses a stable structural interface between the co-polymer and the hydroxyapatite.
- Hydrophilic surface properties here refer to properties that are characteristic of and associated with hydrophilic surfaces, for example, water contact angle below about 100°.
- retaining mechanical integrity in aqueous environment it is meant that the storage modulus of hydrated composite is comparable or better than the storage modulus of the dry composite.
- elasticity refers to the ability of a material, when prepared in an electrospun membrane format with dimensions complying to ASTM D882-97, to undergo tensile deformations of at least about 20% (e.g., preferably at least about 50%>, 75%, 100%, 150% or 200%) prior to failure.
- the hydroxyapatite may be present in any suitable percentage depending on the application at hand.
- the hydroxyapatite is present in a weight percentage of at least 1 % (e.g., at least 5, at least 10%>, at least 20%>, from about 20%> to about 50%), from about 20%> to about 60%>, from about 20%> to about 70%>, from about 1% to about 70%).
- the block co-polymer includes blocks of poly(ethylene glycol) and polyesters. In certain preferred embodiments, the block co-polymer comprises blocks of poly(ethylene glycol) and poly(lactic acid).
- the composition of the invention is characterized by the properties of biodegradability, aqueous stability and eletrospinability.
- the composition may be electrospun into fibrous composite mesh.
- the block co-polymer is crosslinked forming a 3-D polymer-hydroxyapatite network.
- the composition is a 3-D network prepared rapid prototyping.
- the composition is characterized by a shape-memory property.
- Shape-memory property refers to the ability of a material to return from a deformed state (temporary shape) to its original (permanent) shape induced by an external stimulus (trigger), such as a temperature change.
- the invention also features an article of manufacture made from the composition disclosed herein.
- the invention generally relates to a medical implant that includes a composition comprising hydroxyapatite and a block co-polymer, wherein the block copolymer comprises hydrophilic blocks and degradable hydrophobic blocks.
- the implant may be a 3-D filler for bony defects or a repair material for bone, cartilage, osteochondral, tendon or ligament damage.
- the implant is a degradable fibrous membrane wrapped around one or more structural allografts or one or more 3-D synthetic scaffolds to augment tissue repair function.
- the implant is biodegradable. Additionally, it is preferred that the implant is capable of supporting attachment of cells and/or supporting attachment of a biological agent. Any suitable cells may be employed depending on the desired application. In certain preferred embodiment, the cells are stem or progenitor cells.
- the biological agent may be a therapeutic, diagnostic or imaging agent.
- the biological agent attached to the implant is a growth factor or an antibiotic agent.
- the invention generally relates to a biodegradable composite scaffold prepared from a fibrous composite mesh electrospun from a suspension of hydroxyapatite with an amphiphilic block poly(ethylene gly col-co-lactic acid).
- the invention generally relates to a biodegradable, three- dimensional composite scaffold prepared by crosslinking a suspension of hydroxyapatite with an amphiphilic block poly(ethylene glycol-co-lactic acid).
- the invention generally relates to a biodegradable, three- dimensional composite scaffold, prepared by rapid prototyping from a suspension of hydroxyapatite with an amphiphilic block poly(ethylene glycol-co-lactic acid).
- the present invention describes a rational block co-polymer design consisting of hydrophilic and degradable hydrophobic segments. Such a design allows for stable suspension of HA (or similar bioceramics) at high mineral concentrations be made in such a block co-polymer solution, which can be used to develop a variety of scaffold architectures, from 2-D electrospun composite fibrous meshes to 3-D composite scaffolds, all with excellent structural integration between the polymer and mineral component.
- the invention simultaneously addresses several major limitations in prior biomaterial designs, including (1) the lack of degradable yet hydrophilic materials for musculoskeletal applications; (2) the lack of adequate structural integration, thus poor mechanical properties, of organic-inorganic structural composites for orthopedic applications; (3) the difficulty of incorporating high percentage of osteoconductive mineral in synthetic bone substitute without making the composites brittle.
- the stable suspension of a high weight percentage of HA (content close to those in human bone), critical to recapitulate the structure and biological activity of bone, can be achieved without the addition of any surfactants or potentially harmful chemicals.
- Such materials are particularly suitable for load-bearing applications (e.g., tensile and compressive) such as synthetic bone grafts or ligaments.
- the material is thermoplastic and suspends the HA without crosslinking, it can be extruded for use as degradable sutures or other applications (i.e., fused deposition modeling).
- the polymer/HA mixture can also be electrospun into high HA concentration membranes for the augmentation of bone repair in combination with structural allografts or 3-D tissue engineered constructs.
- PEG (20,000 Da) was used to initiate the ring-opening polymerization of cyclic D,L-Lactide forming the block copolymer PLA600-PEG454-PLA600 (PELA) or a composition of 80% w/w PLA and 20% w/w PEG.
- the reaction was performed at 130 °C under inert gas and catalyzed by 500 ppm of Sn(Oct) 2 .
- the resulting polymer was characterized by gas permeation chromatography (GPC) and nuclear magnetic resonance (NMR), representative GPC and NMR data are shown in FIG. 1 and FIG. 2.
- the PELA was dissolved in chloroform and purified by precipitation in methanol.
- HA from 0%> to 50%> w/w
- PELA 50% w/v
- the HA remained stably dispersed in the electrospinning solution for at least 1 week with minimal settling detected which represents a major improvement over previous report (FIG. 3).
- the suspensions were electrospun through an 18G needle at a flow rate of 1.7 mL/hr, a voltage of 12kV, and a working distance of 15 cm (FIG. 4).
- FIG. 5 Representative bright- field images of a HA- free mesh and of a mesh containing 20 w/w HA are shown in FIG. 5.
- XRD confirmed no change in the crystal structure of the hydroxyapatite during the spinning process (FIG. 6).
- Scanning electron microscopy demonstrated that fiber dimensions were relatively uniform. Even with the incorporation of up to 50% w/w HA, HA remained embedded within the fibers with roughened fiber surfaces (FIG. 7). The presence of HA was further confirmed by energy-dispersive x-ray
- the composite meshes exhibit highly elastic properties with recoverable strains of over 100% (FIG. 9).
- 25% HA-PELA composite meshes exhibit ultimate tensile strains of over 200%, as opposed to 25% HA-PLA with an ultimate tensile strain below 40%.
- Dynamic mechanical analysis strain sweep, 1 Hz, 0-200 ⁇ amplitude
- Meshes with 50% HA w/w exhibited a decreased storage modulus but still had high failure strains and excellent handling
- the well-controlled molecular weight and polydispersity allows us to investigate the effect of polymer chemistry on the composite scaffold properties without additional confounding factors.
- Racemic D,L-lactide was chosen over L-lactide due to the accelerated degradation profile of the former and the concern over undesired crystalline degradation by-products of the latter which can elicit adverse responses in vivo.
- DSC Differential scanning calorimetry
- HA Prior to electrospinning, HA was sonicated in 1 :4 dimethylformamide/chloroform to disrupt HA aggregates. PELA or PLA was then added and stirred overnight to produce a polymer/HA suspension. The PELA-HA suspension was stable for over 1 week whereas the HA tended to quickly settle from the PLA solution without immediate electrospinning (FIG. 16). The HA-PELA scaffolds were electrospun without noticeable interference from the HA component while periodic blockage of the needle tip was observed during the electrospinning of HA-PLA composite.
- HA-PELA and HA-PLA composite scaffolds (average thickness of 0.1-0.2 mm) with 0 to 25 wt% HA were obtained after 2 hr and dried in a vacuum oven for 48 hours to remove residual solvent.
- the HA-PELA composites exhibited a narrow distribution of fiber dimensions and fewer defects than HA-PLA (FIGs. 12A & B). While there was no significant difference in fiber diameter between 0% HA-PELA and 25% HA- PELA, the diameter of the 25% HA-PLA fibers increased over two-fold from 0% HA-PLA.
- Thermogravimetric analysis was used to determine the copolymer composition and actual HA content in the electrospun composites (FIG. 12C).
- the 0% HA- PELA TGA curve was characterized with a transition at approximately 83% weight loss, which closely correlated with the weight percentage of PLA in the PELA scaffolds.
- the PLA blocks, with a lower decomposition temperature than PEG, were burnt away first. This transition was not observed in the 10 and 25% HA-PELA composite, likely due to an increase in the decomposition temperature of the composite beyond those associated with the PLA and PELA blocks upon the HA incorporation.
- the HA appears to have a thermal insulating effect on the scaffolds.
- the percentage of HA that remained after PELA thermal decomposition as determined by TGA matched precisely with their weight percentages in the electrospinning solution (10%> and 25%), supporting excellent uniformity and stability of the PELA-HA suspension throughout the electrospinning.
- the actual HA content in the 25% HA-PLA composite as determined by TGA is 28.4%, likely resulting from the inhomogeneous dispersion of HA with PLA and some level of settling/aggregation of HA during the electrospinning.
- the wettability or hydrophilicity of a synthetic tissue scaffold is important for facilitating cell seeding, growth factor loading, and surgical handling.
- the hydrophilicity of the HA-PELA and HA-PLA electrospun composites was assessed by water contact angle measurements (FIG. 13A).
- the hydrophilic PEG block in PELA significantly reduced the water contact angle (increased the wettability) of the scaffolds when compared to PLA.
- HA incorporation slightly increased the contact angle of the vacuum-dried as-spun PELA while exerted no significant effect on the wettability of PLA. It is possible that the preferential interaction between the PEG blocks with HA has made them less exposed to the surface, contributing to the slight reduction in wettability of HA-PELA.
- MSCs Mesenchymal stem cells residing in the bone marrow
- osteoblasts chondrocytes, adipocytes, and myoblasts.
- chondrocytes chondrocytes
- adipocytes adipocytes
- myoblasts a variety of cell types including osteoblasts, chondrocytes, adipocytes, and myoblasts.
- An effective synthetic tissue scaffold should support the attachment and guide lineage-specific differentiations of MSCs, allowing for effective regeneration of tissues of interest.
- rMSC rat bone marrow stromal cell
- the non-fouling PEG block and the osteoconductive HA component of the HA-PELA composites are expected to exhibit opposite effects on protein and cell adhesion.
- Un- mineralized di-block or tri-block PELA have been used as anti-adhesion membranes, with their low protein adsorption characteristics attributed to the non-fouling PEG exposed on the surface in the aqueous environment. (Yang, et al. 2009 Acta Biomater. 5, 2467-74;
- HA is known for its ability to absorb a wide range of proteins due to its dynamic surface properties ⁇ e.g., pH-dependent zeta potential) and large surface area (for HA nanocrystals) and promote cell attachment.
- dynamic surface properties e.g., pH-dependent zeta potential
- large surface area for HA nanocrystals
- HA dose-dependent increases in viable adherent cells at 24 h were observed, supporting that HA promoted MSC attachment to the amphiphilic polymer.
- MSCs adhered on all substrates were able to proliferate well as indicated by MTT cell viability at 96 hr, irrespective of the chemical environment and mineralization status.
- rMSCs To examine the effects of dose-dependent HA incorporation in PELA and PLA on the spontaneous lineage commitment of MSCs, we cultured rMSCs on 0-25% HA-PELA scaffolds along with 25% HA-PLA control in expansion media without differentiation inducing supplements. After 7, 14, or 21 days, total RNA was isolated from cells adhered to each scaffold and the gene expression of typical osteoblast, chondrocyte, and adipocyte markers as a function of the scaffold environment and time was quantified by qPCR (FIG. 15). Data were normalized to those obtained from the rMSCs prior to seeding on the various substrates (time 0).
- HA incorporation resulted in dose-dependent increases in the expression of chondrogenic marker Sox9 and osteogenic marker osteocalcin as early as 7 days, with the HA dose-dependent trend persisting even when the overall expression of these markers started to decline at later time points.
- the decline of the overall expression of these phenotypical markers at later time points can be attributed to both the temporal nature of the expression, observed with other tissue-engineering scaffolds, and the un-stimulated culture condition that may be insufficient to drive potent and persistent expression of these markers.
- osteochondral lineage markers was significantly higher for MSCs cultured on 25% HA- PELA scaffolds than for those cultured on 25% HA-PLA, suggesting that the osteochondro- inductive properties of HA are more effectively manifested on HA-PELA where HA were more homogeneously dispersed.
- adipogenic marker PPARG significantly decreased upon the addition of HA to PELA in a dose-dependent manner at all time points examined. Furthermore, the expression of PPARG in MSCs cultured on the 25% HA-PLA scaffold is significantly higher than those cultured on the 25% HA-PELA scaffold, and the adipogenic lineage commitment promoted by the more hydrophobic HA-PELA peaked at 21 days. Overall, these data show that the PELA-HA composites promote early osteochondral lineage commitment while suppress adipogenic lineage commitment of MSCs under un-stimulated culture conditions. By contrast, such effects of HA incorporation were not manifested on the PLA-HA composite, where significantly lower osteochondral gene expressions and more elevated adipocyte maker expression were observed instead.
- a CAD of a macroporous cylindrical scaffold was designed using 3-matics
- the CAD file was processed into g-code for 3-D printing by ReplicatorG.
- a MakerBot Thing-O-Matic 3D printer (MakerBot Industries) was used to rapid prototype the PELA and PELA-HA scaffolds by fused deposition modeling. The printer built the scaffolds layer-by-layer by thermal extrusion. Extruder temperatures of 140 °C, 160 °C, and 185 °C were used for 0% HA-PELA, 10% HA-PELA, and 25% HA-PELA scaffolds, respectively (FIG. 18A; FIG. 19).
- Hydroxyapatite was purchased from Alfa Aesar. All other solvents and reagents were purchased from Sigma- Aldrich and used as received.
- Poly(ethylene glycol-co-lactic acid), PELA was synthesized by melt ring opening polymerization. Briefly, poly(ethylene glycol) (4 g, 0.2 mmol) was heated to 100 °C in a shlenk flask and stirred under vacuum for 1 hr to remove residual water. The melt was cooled to room temperature before Tin(II) 2- ethylhexanoate (24.18 mg, 0.06 mmol) in anhydrous toluene was introduced by syringe. The toluene was removed by heating the mixture under vacuum at 100 °C for 15 min.
- Molecular weight and polydispersity of PELA and PLA was determined by gel permeation chromatography (GPC) on a Varian Prostar HPLC system equipped with two 5- mm PLGel MiniMIX-D columns (Agilent) and a PL-ELS2100 evaporative light scattering detector (Polymer Laboratories). THF was used as an eluent at 0.3 mL/hr at room temperature. Molecular weight and polydispersity was calculated based on EasiVial polystyrene standards (Agilent).
- Thermal transitions of PELA and HA-PELA composites were determined by conventional differential scanning calorimetry (DSC) on a Q200 MDSC (TA Instruments). Samples ( ⁇ 6 mg) were scanned twice from -90°C to 250°C (20°C/min). A constant nitrogen flow of 50 mL/min was applied. Temperature was calibrated with indium, gallium, and tin standards. T g was defined as the midpoint of the inflection tangent from the second heating curve.
- Electrospining PELA-HA and PLA-HA composite scaffolds with 0-25 wt% HA were prepared by electrospinning. HA was bath-sonicated in 5-mL 1 :4
- As-spun scaffolds were sputter coated in Au (4nm) and imaged on a Quanta 200 FEG MKII SEM (FEI Inc.) under high vacuum at 5 kV. Fiber diameter was quantified from the SEM micrographs by measuring 100 random fibers with ImageJ software (National Institutes of Health).
- TGA was used to determine the actual percentage of HA in the as-spun scaffolds.
- the samples were heated at a rate of 20 °C/min. from room temperature to 500°C and the mass change was recorded on a TGA Q50 (TA Instruments). HA powder was used as a control.
- the wettability of the scaffolds was examined by the sessile drop technique. 5- ⁇ , droplets of deionized water were deposited onto as-spun scaffolds or scaffolds freeze-dried following 24 hr equilibration in 37°C deionized water. The water contact angle was recorded using a CAM 200 goniometer (KSV Instruments). The droplet was imaged after 30 sec. and the average contact angle from the left and right side of the drop was recorded. Five randomly selected areas per scaffold were used for each water contact angle measurement.
- the tensile storage modulus of dry and hydrated (deionized water) scaffolds was determined on a Q800 DMA (TA Instruments). Specimens (5.3 mm x 20 mm) were cut with a parallel blade cutter and loaded onto a film tension fixture with a grip separation of 10 mm. Dry and hydrated samples were applied with a 0.001 N and 0.05 N pre-load force, respectively. Samples were equilibrated at 37°C and held isothermal for 10 min. prior to initiating 0.02% strain at a frequency 1 Hz. The 0.02% strain was chosen as it falls within the linear viscoelastic region of the scaffolds. The storage modulus at 0.02%> strain was recorded.
- Rat bone marrow stromal cells were isolated from the long bones of a 4- week old male Charles River SASCO SD rat as previously described. Briefly, whole bone marrow was flushed from the femur with minimal essential medium (aMEM without ascorbic acid) and the red blood cells were lysed with sterile water. The cells were
- Non-adherent cells were aspirated 4 days after platting and remaining adherent cells were cultured until 70% confluence before being trypsinized and seeded on various scaffolds.
- rMSCs were cultured on the scaffolds in expansion media to determine the effect of scaffold composition on un-stimulated lineage commitment. Scaffolds were sterilized under UV for 1 h each side and equilibrated in MSC expansion media at 37°C overnight. The scaffolds were placed in ultra-low attachment 24 well plates (Corning) and seeded with passage 1 rMSCs (50,000 /cm 2 ). Following 7, 14, or 21 days in culture, total RNA from the MSCs adhered on the scaffolds and from P0 rMSCs (prior to seeding on scaffolds, time 0) was isolated using TRIzol (Invitrogen) and purified by Direct-Zol miniprep (Zymo Research). RNA was reverse transcribed into cDNA with Superscript III Reverse Transcriptase
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Textile Engineering (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Mechanical Engineering (AREA)
- Materials For Medical Uses (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
L'invention propose de nouvelles compositions d'hydroxyapatite et de copolymères à blocs, des procédés de leur préparation et des utilisations de ceux-ci, les copolymères ayant des blocs hydrophobes dégradables et des blocs hydrophiles dégradables pour réaliser une interface stable avec l'hydroxyapatite, conduisant à des suspensions polymère-hydroxyapatite stables. La super-hydrophilicité, l'intégrité mécanique renforcée et l'intégrité structurale conservée du composite HA-PELA dans un environnement aqueux représentent des avantages majeurs par rapport aux composites HA-PLA pour des applications d'ingénierie de tissu squelettique.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12834037.9A EP2768896A4 (fr) | 2011-09-23 | 2012-09-21 | Composites de polymères à teneur élevée en minéraux, élastomères et dégradables |
CA2849891A CA2849891A1 (fr) | 2011-09-23 | 2012-09-21 | Composites de polymeres a teneur elevee en mineraux, elastomeres et degradables |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161538223P | 2011-09-23 | 2011-09-23 | |
US61/538,223 | 2011-09-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013044078A2 true WO2013044078A2 (fr) | 2013-03-28 |
WO2013044078A3 WO2013044078A3 (fr) | 2015-05-07 |
Family
ID=47915102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/056641 WO2013044078A2 (fr) | 2011-09-23 | 2012-09-21 | Composites de polymères à teneur élevée en minéraux, élastomères et dégradables |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2768896A4 (fr) |
CA (1) | CA2849891A1 (fr) |
WO (1) | WO2013044078A2 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014204634A1 (fr) * | 2013-05-31 | 2014-12-24 | University Of Massachusetts Medical School | Échafaudages composites, minéraux, polymères, dégradables et élastomères |
WO2016181402A1 (fr) | 2015-05-14 | 2016-11-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Traitement de polymères thermodurcis à mémoire de forme pour obtenir des formes 3d complexes |
WO2018120560A1 (fr) * | 2016-12-29 | 2018-07-05 | 中国科学院深圳先进技术研究院 | Composite à base de polymère comprenant un réseau tridimensionnel de particules de charge et procédé de préparation associé |
CN109646715A (zh) * | 2019-01-25 | 2019-04-19 | 上海交通大学医学院附属第九人民医院 | 电纺3d打印制备含细胞因子微球的多层软骨复合体 |
-
2012
- 2012-09-21 WO PCT/US2012/056641 patent/WO2013044078A2/fr active Application Filing
- 2012-09-21 EP EP12834037.9A patent/EP2768896A4/fr not_active Withdrawn
- 2012-09-21 CA CA2849891A patent/CA2849891A1/fr not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of EP2768896A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014204634A1 (fr) * | 2013-05-31 | 2014-12-24 | University Of Massachusetts Medical School | Échafaudages composites, minéraux, polymères, dégradables et élastomères |
EP3003224A4 (fr) * | 2013-05-31 | 2016-11-23 | Univ Massachusetts Medical | Échafaudages composites, minéraux, polymères, dégradables et élastomères |
WO2016181402A1 (fr) | 2015-05-14 | 2016-11-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Traitement de polymères thermodurcis à mémoire de forme pour obtenir des formes 3d complexes |
WO2018120560A1 (fr) * | 2016-12-29 | 2018-07-05 | 中国科学院深圳先进技术研究院 | Composite à base de polymère comprenant un réseau tridimensionnel de particules de charge et procédé de préparation associé |
CN109646715A (zh) * | 2019-01-25 | 2019-04-19 | 上海交通大学医学院附属第九人民医院 | 电纺3d打印制备含细胞因子微球的多层软骨复合体 |
Also Published As
Publication number | Publication date |
---|---|
WO2013044078A3 (fr) | 2015-05-07 |
EP2768896A2 (fr) | 2014-08-27 |
EP2768896A4 (fr) | 2016-06-22 |
CA2849891A1 (fr) | 2013-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kutikov et al. | An amphiphilic degradable polymer/hydroxyapatite composite with enhanced handling characteristics promotes osteogenic gene expression in bone marrow stromal cells | |
Degli Esposti et al. | Highly porous PHB-based bioactive scaffolds for bone tissue engineering by in situ synthesis of hydroxyapatite | |
US20140088618A1 (en) | Elastomeric and degradable high-mineral content polymer composites | |
Shin et al. | Stimulated myoblast differentiation on graphene oxide-impregnated PLGA-collagen hybrid fibre matrices | |
Hivechi et al. | Investigation of morphological, mechanical and biological properties of cellulose nanocrystal reinforced electrospun gelatin nanofibers | |
Huang et al. | 3-D printed porous cellulose acetate tissue scaffolds for additive manufacturing | |
Lahiri et al. | Boron nitride nanotube reinforced polylactide–polycaprolactone copolymer composite: Mechanical properties and cytocompatibility with osteoblasts and macrophages in vitro | |
Hong et al. | Nano-composite of poly (L-lactide) and surface grafted hydroxyapatite: mechanical properties and biocompatibility | |
US9181636B2 (en) | Electrospun ceramic-polymer composite as a scaffold for tissue repair | |
Liu et al. | Surface modification of bioactive glass nanoparticles and the mechanical and biological properties of poly (L-lactide) composites | |
Mi et al. | Morphology, mechanical properties, and mineralization of rigid thermoplastic polyurethane/hydroxyapatite scaffolds for bone tissue applications: effects of fabrication approaches and hydroxyapatite size | |
Song et al. | Electrospun hydroxyapatite grafted poly (L-lactide)/poly (lactic-co-glycolic acid) nanofibers for guided bone regeneration membrane | |
Senatov et al. | Polyhydroxybutyrate/hydroxyapatite highly porous scaffold for small bone defects replacement in the nonload-bearing parts | |
Cao et al. | Cell adhesive and growth behavior on electrospun nanofibrous scaffolds by designed multifunctional composites | |
Keivani et al. | Engineered electrospun poly (caprolactone)/polycaprolactone-g-hydroxyapatite nano-fibrous scaffold promotes human fibroblasts adhesion and proliferation | |
Dias et al. | 3D‐printed cryomilled poly (ε‐caprolactone)/graphene composite scaffolds for bone tissue regeneration | |
Gil-Castell et al. | Tailored electrospun nanofibrous polycaprolactone/gelatin scaffolds into an acid hydrolytic solvent system | |
Plath et al. | Zein supports scaffolding capacity toward mammalian cells and bactericidal and antiadhesive properties on poly (ε-caprolactone)/zein electrospun fibers | |
Montanheiro et al. | Evaluation of cellulose nanocrystal addition on morphology, compression modulus and cytotoxicity of poly (3-hydroxybutyrate-co-3-hydroxyvalerate) scaffolds | |
Koushki et al. | A new injectable biphasic hydrogel based on partially hydrolyzed polyacrylamide and nanohydroxyapatite as scaffold for osteochondral regeneration | |
WO2018102796A1 (fr) | Polymères à mémoire de forme amphiphiles biodégradables et compositions et procédés associés | |
Chen et al. | Tailoring chemical and physical properties of fibrous scaffolds from block copolyesters containing ether and thio-ether linkages for skeletal differentiation of human mesenchymal stromal cells | |
Nájera et al. | 3D Printed PLA/PCL/TiO2 composite for bone replacement and grafting | |
Tiwari et al. | Nano-nets covered composite nanofibers with enhanced biocompatibility and mechanical properties for bone tissue engineering | |
Shokrollahi et al. | Biological and mechanical properties of novel composites based on supramolecular polycaprolactone and functionalized hydroxyapatite |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase in: |
Ref document number: 2849891 Country of ref document: CA |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012834037 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12834037 Country of ref document: EP Kind code of ref document: A2 |